What is the diagnosis and treatment for a patient with bleeding behind the eye, possibly taking anticoagulants like warfarin or aspirin?

Bleeding Behind the Eye: Diagnosis and Management in Anticoagulated Patients

Immediate Diagnostic Approach

Bleeding behind the eye in a patient on anticoagulants requires urgent ophthalmologic evaluation to distinguish between vision-threatening hemorrhages (vitreous, subretinal, retrobulbar, or intraocular) versus less critical bleeding, as the location determines both prognosis and anticoagulation management. 1

Critical Diagnostic Elements

• Perform dilated fundoscopic examination with indirect ophthalmoscopy and scleral depression to identify the specific bleeding location: vitreous hemorrhage, subretinal hemorrhage, retrobulbar hemorrhage, or intraocular bleeding 1
• Assess visual acuity immediately, as monocular vision changes or blindness indicate intraocular hemorrhage requiring emergent intervention 1
• Check for proptosis, severe eye pain, and ophthalmoplegia, which suggest retrobulbar hemorrhage with potential for central retinal artery occlusion and permanent vision loss 2
• Obtain B-scan ultrasonography if media opacity prevents adequate fundoscopic examination to search for retinal tears, retinal detachment, or mass lesions causing the hemorrhage 1

Laboratory Assessment

• Measure INR immediately in warfarin patients to determine degree of anticoagulation and guide reversal decisions 1
• Document hemoglobin and assess for hemodynamic instability (systolic BP <90 mmHg, heart rate elevation, orthostatic changes) to classify bleeding severity 1

Classification of Bleeding Severity

Major (Vision-Threatening) Ocular Bleeding

Intraocular hemorrhage is classified as a critical site bleed with potential for permanent vision loss, requiring immediate anticoagulation reversal consideration 1:

• Retrobulbar hemorrhage: Can cause central retinal artery occlusion, optic nerve compression, and blindness within hours 2
• Massive subretinal hemorrhage: Associated with permanent vision loss, particularly in anticoagulated patients where bleeding is more extensive 3
• Dense vitreous hemorrhage obscuring all retinal details: Prevents assessment for underlying retinal tears and increases risk of retinal detachment 1

Non-Major Ocular Bleeding

• Mild-moderate vitreous hemorrhage with visible retina: Often clears spontaneously with observation 1
• Small subconjunctival hemorrhage: Benign, self-limited, requires no intervention 1

Anticoagulation Management Algorithm

For Major (Vision-Threatening) Ocular Bleeding

Immediately withhold warfarin and consider reversal therapy for any intraocular hemorrhage threatening vision 1, 4:

Warfarin Reversal Protocol

• For INR 2.0-5.0 with major ocular bleeding: Withhold warfarin and administer vitamin K 5-10 mg by slow IV infusion over 30 minutes 1, 4
• For INR >5.0 with major ocular bleeding: Administer four-factor prothrombin complex concentrate (4F-PCC) 25-50 units/kg based on INR level, plus vitamin K 5-10 mg IV 1, 5
  • INR 2 to <4: 25 units/kg
  • INR 4-6: 35 units/kg
  • INR >6: 50 units/kg 1
• Target INR <1.5 for life-threatening intraocular bleeding to achieve hemostasis 5

Direct Oral Anticoagulant (DOAC) Reversal

• For apixaban or rivaroxaban: Administer andexanet alfa per dosing protocol, or 4F-PCC if andexanet unavailable 1
• For dabigatran: Administer idarucizumab 5g IV 1

For Non-Major Ocular Bleeding

Continue anticoagulation without interruption for minor ocular bleeding such as small vitreous hemorrhages or subconjunctival hemorrhages 1, 4:

• Withhold one dose of warfarin only if INR is supratherapeutic (>3.5), then resume at usual maintenance dose 4
• Do not routinely stop aspirin, as it has minimal effect on ocular bleeding risk 6

Special Considerations for Surgical Intervention

Vitreoretinal Surgery in Anticoagulated Patients

Warfarin can be safely continued for most vitreoretinal procedures if INR is in therapeutic range (2.0-3.0), as strabismus and vitreoretinal surgeons routinely operate on anticoagulated patients 1, 7:

• No increase in suprachoroidal hemorrhage or major complications was found in patients continuing warfarin (INR median 2.3) compared to controls 7
• Aspirin should not be stopped prior to vitreoretinal surgery, as it has little effect on surgical bleeding 6
• Consider withholding warfarin only if INR >3.0 or patient has additional bleeding risk factors (age >75, renal failure, concomitant antiplatelet drugs) 1, 6

Bridging Anticoagulation for High-Risk Patients

For patients with mechanical heart valves (especially mitral position) or recent thromboembolism requiring warfarin interruption, initiate therapeutic-dose heparin when INR falls below 2.0 1:

• Start unfractionated heparin or LMWH 48 hours before surgery when warfarin is held 1
• Stop heparin 4-6 hours before procedure, restart as early as bleeding stability allows 1
• Continue heparin until INR is therapeutic for >48 hours after warfarin restart 1, 4

Common Clinical Scenarios

Vitreous Hemorrhage in Anticoagulated Patients

• Patients on warfarin with rhegmatogenous retinal detachment are 3 times more likely to present with vitreous hemorrhage compared to non-anticoagulated patients 7
• If vitreous hemorrhage obscures fundus examination, perform weekly B-scan ultrasonography until hemorrhage clears enough for indirect ophthalmoscopy with scleral depression 1
• Consider early vitrectomy (within 7 days) for dense vitreous hemorrhage to reduce risk of macula-involving retinal detachment 1

Recurrent Vitreous Hemorrhage

• Warfarin significantly increases risk of postoperative re-bleeding after diabetic vitrectomy (relative risk 6.185) 6
• For recurrent hemorrhage from retinal arterial macroaneurysm in anticoagulated patients, consider laser photocoagulation or endolaser during vitrectomy 8

Retrobulbar Hemorrhage

• This is a vision-threatening emergency requiring immediate intervention with lateral canthotomy/cantholysis if intraocular pressure is elevated 2
• Patients on both aspirin and warfarin have markedly increased risk of uncontrolled retrobulbar bleeding 2

Critical Pitfalls to Avoid

• Never withhold warfarin for minor ocular procedures (cataract surgery, glaucoma surgery) where bleeding is minimal and easily controlled 1
• Never use high-dose vitamin K (≥10 mg) for non-bleeding situations, as this creates warfarin resistance for up to one week 4
• Never abruptly discontinue warfarin in high-risk patients without bridging, as thrombosis markers increase with cessation 1, 4
• Do not confuse anticoagulant management with antiplatelet management—aspirin can generally be continued for ocular procedures 9, 6
• Do not delay ophthalmologic consultation for any patient with vision changes and ocular bleeding, as hours matter for retinal artery occlusion 1, 2

Restarting Anticoagulation

Resume warfarin at usual maintenance dose once adequate hemostasis is achieved and vision is stable 4:

• For non-major bleeding, restart within 24-48 hours after initial management 1
• For major bleeding requiring reversal, restart when bleeding risk has resolved (typically 7-14 days for intraocular hemorrhage) 1
• Recheck INR within 24-48 hours after restart and continue monitoring every 24-48 hours until stable in therapeutic range 4, 5